Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz R, Gouttebel MC, Moindrot H, Boyer JD, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau JM, Hedelius F, Moraillon A, Chapuis F, Bleuse JP, Barbier Y, Heilmann MO, Valette PJ. Trillet-Lenoir V, et al. Among authors: lledo g. Br J Radiol. 2002 Nov;75(899):903-8. doi: 10.1259/bjr.75.899.750903. Br J Radiol. 2002. PMID: 12466256
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Louvet C, et al. Among authors: lledo g. J Clin Oncol. 2005 May 20;23(15):3509-16. doi: 10.1200/JCO.2005.06.023. J Clin Oncol. 2005. PMID: 15908661 Clinical Trial.
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M, Tournigand C, Lledo G, Mabro M, André T, Louvet C, Aparicio T, Flesch M, Varette C, de Gramont A; Oncology Multidisciplinary Research Group (GERCOR). Hebbar M, et al. Among authors: lledo g. Cancer Invest. 2006 Mar;24(2):154-9. doi: 10.1080/07357900500524397. Cancer Invest. 2006. PMID: 16537184 Clinical Trial.
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G, Bengrine-Lefevre L, Maindrault-Goebel F, Louvet C, de Gramont A. Bidard FC, et al. Among authors: lledo g. Ann Oncol. 2009 Jun;20(6):1042-7. doi: 10.1093/annonc/mdn730. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153116 Free article. Clinical Trial.
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
Chibaudel B, Tournigand C, Artru P, André T, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Rivera F, Perez-Staub N, Louvet C, de Gramont A. Chibaudel B, et al. Among authors: lledo g. Ann Oncol. 2009 Aug;20(8):1383-6. doi: 10.1093/annonc/mdp012. Epub 2009 May 22. Ann Oncol. 2009. PMID: 19465426 Free article. Clinical Trial.
107 results